Comparison of postoperative complications of ileal conduits versus orthotopic neobladders.
Bladder cancer (BC)
complication
ileal conduit (IC)
neobladder (NB)
radical cystectomy (RC)
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
ppublish
Résumé
Radical cystectomy (RC) and urinary diversion (UD), with either an ileal conduit (IC) or an orthotopic neobladder (NB), is a complex surgery, in which various complications can occur. In this study, we compared postoperative complication rates after a RC and UD performed for the treatment of muscle-invasive bladder cancer or recurring high-risk non-muscle-invasive bladder cancer in our center. We retrospectively included 604 patients that underwent UDs from December 1996 to August 2015. Complications were classified by type and severity according to the Clavien-Dindo classification (CDC). Univariate and multivariate analyses were performed to identify predictive factors of short-term (≤30 d), intermediate-term (31-90 d), and long-term (>90 d) complications. Four hundred and forty-five (74%) and 159 (26%) patients received ICs and NBs, respectively. These groups had significantly different long-term complication rates (IC: 39.7% The increasing risk of short-term complications with increasing aCCI and ASA score can be used when counseling the patients who are planned to undergo a RC with UD. Patients that receive NBs should be informed of the increased risk of reoperations compared to an IC.
Sections du résumé
BACKGROUND
BACKGROUND
Radical cystectomy (RC) and urinary diversion (UD), with either an ileal conduit (IC) or an orthotopic neobladder (NB), is a complex surgery, in which various complications can occur. In this study, we compared postoperative complication rates after a RC and UD performed for the treatment of muscle-invasive bladder cancer or recurring high-risk non-muscle-invasive bladder cancer in our center.
METHODS
METHODS
We retrospectively included 604 patients that underwent UDs from December 1996 to August 2015. Complications were classified by type and severity according to the Clavien-Dindo classification (CDC). Univariate and multivariate analyses were performed to identify predictive factors of short-term (≤30 d), intermediate-term (31-90 d), and long-term (>90 d) complications.
RESULTS
RESULTS
Four hundred and forty-five (74%) and 159 (26%) patients received ICs and NBs, respectively. These groups had significantly different long-term complication rates (IC: 39.7%
CONCLUSIONS
CONCLUSIONS
The increasing risk of short-term complications with increasing aCCI and ASA score can be used when counseling the patients who are planned to undergo a RC with UD. Patients that receive NBs should be informed of the increased risk of reoperations compared to an IC.
Identifiants
pubmed: 33457228
doi: 10.21037/tau-20-713
pii: tau-09-06-2541
pmc: PMC7807350
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2541-2554Informations de copyright
2020 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-713). The authors have no conflicts of interest to declare.
Références
Curr Opin Urol. 2015 Nov;25(6):570-7
pubmed: 26372035
Turk J Urol. 2019 Dec 1;45(Supp. 1):S150-S155
pubmed: 32027599
Cancer. 2010 Jan 15;116(2):331-9
pubmed: 19924831
Can Urol Assoc J. 2013 Sep-Oct;7(9-10):E552-60
pubmed: 24069095
Ann Surg. 2002 Jun;235(6):803-13
pubmed: 12035036
World J Urol. 2020 Aug;38(8):1959-1968
pubmed: 31691084
BJU Int. 2012 Dec;110(11 Pt B):E756-64
pubmed: 23107013
World J Urol. 2019 Sep;37(9):1857-1866
pubmed: 30519746
J Urol. 2010 Sep;184(3):990-4; quiz 1235
pubmed: 20643429
BJU Int. 2014 Jan;113(1):11-23
pubmed: 24330062
Springerplus. 2016 May 17;5:646
pubmed: 27330912
Urology. 2007 Jan;69(1 Suppl):17-49
pubmed: 17280907
Eur Urol. 2013 Jan;63(1):67-80
pubmed: 22995974
Eur Urol. 2009 Jan;55(1):164-74
pubmed: 18675501
Ann Surg Oncol. 2015 Mar;22(3):1032-42
pubmed: 25164037
World J Urol. 2009 Feb;27(1):45-50
pubmed: 19020881
Eur Urol. 2014 Apr;65(4):778-92
pubmed: 24373477
Eur Urol. 2012 May;61(5):1039-47
pubmed: 22381169
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Int J Urol. 2014 Feb;21(2):143-9
pubmed: 23906282
Scand J Urol. 2016 Dec;50(6):439-444
pubmed: 27686879
Int J Clin Oncol. 2018 Aug;23(4):734-741
pubmed: 29442282
Expert Rev Anticancer Ther. 2014 Apr;14(4):419-30
pubmed: 24483953
Urol Oncol. 2015 Dec;33(12):505.e1-7
pubmed: 26282902
Eur Urol. 2012 Feb;61(2):341-9
pubmed: 22074761
Clin Genitourin Cancer. 2016 Jun;14(3):244-8
pubmed: 26362072
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Urol. 2014 Jun;21(6):554-9
pubmed: 24304154